Unlike the standard chemotherapy regimen TCHP, the newer drug T-DXd can cross the blood-brain barrier. This is a crucial advantage for high-risk HER2-positive breast cancer patients, as it offers the potential to prevent brain metastases, a common and devastating site of recurrence for this cancer subtype.

The GSK3 inhibitor was developed for CNS diseases, requiring high specificity and the ability to cross the blood-brain barrier. These same pharmaceutical characteristics—potency and lipophilicity—proved highly advantageous for treating cancer, demonstrating an unexpected but effective therapeutic pivot from neuroscience to oncology.

A non-obvious consequence of effective modern cancer drugs is that patients live longer, allowing more time for cancer cells to metastasize to the central nervous system. The brain's protective blood-brain barrier then ironically shields these new tumors from treatment, creating a growing patient population.

Actuate’s drug was designed to be highly lipophilic (fat-soluble) to cross the blood-brain barrier for CNS treatment. This same property proved crucial for its success in oncology, as it allows the drug to easily penetrate cancer cell membranes and reach the nucleus.

The development of new KIT inhibitors like bezuclastinib is largely fueled by the need for alternatives to high-dose avapritinib in advanced SM. Concerns about cognitive effects and rare intracranial hemorrhage with avapritinib create an opportunity for agents with less blood-brain barrier penetration.

The challenge of getting drugs into the brain is being solved, as proven by Denali's recent FDA approval for a drug using its BBB shuttle for Hunter disease. This, combined with Roche's promising Alzheimer's data with a similar technology, provides hard evidence that these platforms work, driving significant M&A and investment activity.

Unlike the intact blood-brain barrier, the blood-tumor barrier within brain metastases is permeable. This "leakiness" allows large molecules like the ADC trastuzumab deruxtecan (TDXD) to enter and deliver its payload, providing a mechanism for its high CNS efficacy.

Beyond improving progression-free survival, the targeted therapy vorasidenib also provides a significant quality-of-life benefit by improving seizure control. Seizures are a common presenting symptom for low-grade glioma patients, and this added therapeutic effect makes the drug a more holistic treatment option.

While zongertinib demonstrates high systemic efficacy with a 77% response rate, its efficacy in the central nervous system (CNS) is significantly lower at 44%. This gap highlights a critical challenge for patients with brain metastases and underscores the need for combination therapies or next-generation drugs with better CNS penetration.